ALK and non-small cell lung carcinoma: Encouraged by these results, a clinical trial is currently underway in NSCLC patients with the aim to evaluate the performance of exosomal-based EML4-ALK fusion detection in comparison to IHC-based detection of the rearrangement in tissue.